News

The US Food and Drug Administration (FDA) had approved DALVANCE in May 2014 and it was the first drug to be approved as a Qualified Infectious Disease Product

Enrollment into four dose groups has been completed (25, 50, 100 and 150 mg) and no drug related adverse events have been reported. The fifth dose group (225

"Our new antibody platform Ylanthia is being used in a rising number of therapeutic relationships including our recent alliances with Merck Serono and Temple University. In addition to

The Butrans Transdermal System is also approved to allow the use of two patches to facilitate dose adjustments during titration. The total dose from both patches should not

Specifically, clinical study CTH-105 will be initiated per the proposal submitted to the FDA under the Company´s Investigational New Drug (IND) application. APL-130277 is an easy-to-administer, fast-acting reformulation

The allowed patent, which is published as US Patent Application 20140072615, is based on Agile’s prior patent, US 7,384,650, covering the formulation for Twirla. "We believe the allowance

The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as

The phase III trial will compare daratumumab in combination with bortezomib, melphalan and prednisone to bortezomib, melphalan and prednisone alone as front line treatment for patients who are

This could result in a total of 34 medicines being sold through pharmacies without prescription. The list includes medicines for the treatment of migraine, acid-reflux symptoms, hay fever,